Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFDERP)

Drug Name	PMID28870136-Compound-52 Drug Info
Cross-matching ID	PubChem CID 2519 ChEBI ID CHEBI:27732 CAS Number CAS 58-08-2 TTD Drug ID DMFDERP ACDINA Drug ID D00088

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
AB680	DMGONUE	Pancreatic cancer	2C10	Phase 1	[4]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
CPI-006	DMJSFTX	Advanced cancer	2A00-2F9Z	Phase 1	[6]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[1]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[1]
PMID28870136-Compound-53	DMLEWY6	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
2	Clinical pipeline report, company report or official report of Agenus.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
5	ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
6	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
7	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
8	Clinical pipeline report, company report or official report of Surface oncology.